While high levels of EZH2 expression were associated with poor OS and relapse-free survival (RFS) in patients with HCC, intriguingly, Xiao et al. (2019) reported that low EZH2-expressing HCC that co-expressed PD-L1 (PD-L1+/EZH2low) was linked to poorer OS and RFS [38]. The gene discussed is EZH2; the disease is hepatocellular carcinoma.